Skip to content

Prognostic Score in Covid-19

Identification of a Clinical Score to Support the Clinician in Phase 2 of Covid-19

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04780373
Enrollment
200
Registered
2021-03-03
Start date
2020-04-01
Completion date
2020-12-01
Last updated
2021-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid19 Prognostic Parameters

Brief summary

The aim of the study is to define the clinical and biochemical parameters that characterize COVID-19 patients with a negative prognostic evolution. Our clinical score will be capable to recognize patient with favorable prognosis or patient with poor prognosis by statistical data analysis.

Interventions

OTHERdata collection

clinical data collection

Sponsors

University of L'Aquila
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* patients over 18 and symptomatic and positive for COVID-19 by polymerase chain reaction assay for rhino-pharingeal swab

Exclusion criteria

* Under 18

Design outcomes

Primary

MeasureTime frameDescription
Data collection of clinical and demographical parameters of patients affected by COVID-198 monthsData about sex, age, symptom start date, vital parameters, comorbidity, symptoms, hematochemicals blood tests, therapy, oxygen support, radiology, condition evaluation will be manual collected.

Secondary

MeasureTime frameDescription
Application of statistical analysis on data of patients affected by COVID-192 monthsThe collected data will be analyzed through descriptive statistics analysis, ROC curves, regression analysis, and Machine Learning techniques to predict the prognosis of patients affected by COVID-19.

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 14, 2026